Analyst consensus rating
Kiniksa Pharmaceuticals International Analyst Rating: Strong Buy
Direct answer
Kiniksa Pharmaceuticals International's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $98.00.
Forecast evidence checked October 19, 2026.
Get free Kiniksa Pharmaceuticals International email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $78.59
- Average price target
- $98.00
- High price target
- $108.00
- Low price target
- $87.00
- Low target gap
- +10.7%
- Target upside
- +24.7%
- High target gap
- +37.4%
- Target range width
- 26.7%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International has a verified Strong Buy consensus. The same dataset has an average price target of $98.00.
How far are Kiniksa Pharmaceuticals International's low and high targets from the recorded price?
The low target implies +10.7%, while the high target implies +37.4%.
How many analysts are included in Kiniksa Pharmaceuticals International's consensus?
The verified consensus includes 8 analysts.
How is Kiniksa Pharmaceuticals International's target upside or downside calculated?
The average target of $98.00 is divided by the recorded price of $78.59, then one is subtracted to produce +24.7%. This does not guarantee a future return.
When was Kiniksa Pharmaceuticals International's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.